Related Experiment Video
Updated: May 23, 2025
Author Spotlight: Collecting the Brain and Serum from the Same Mice Fetus to Study Brain Tumor Development
Published on: May 17, 2024
Gestational Exposure to Valproate and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in
Chittaranjan Andrade1, Natarajan Varadharajan2, Sharmi Bascarane3
1Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India.
Insights
Valproate exposure during pregnancy significantly increases the risk of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children. Higher doses of valproate are associated with a substantially elevated risk of ASD.
Area of Science:
- Neurodevelopmental disorders
- Pregnancy and childbirth
- Pharmacology
Background:
- Valproate is a medication with known risks during pregnancy, including major congenital malformations.
- Previous research has not comprehensively evaluated the association between gestational valproate exposure and the risks of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD).
Purpose of the Study:
- To conduct a meta-analysis examining the risk of ASD and ADHD in children following gestational exposure to valproate.
- To assess trimester-specific risks and the impact of valproate dosage on these outcomes.
Main Methods:
- A systematic literature search was performed across MEDLINE, Embase, and Scopus databases.
- Eight cohort studies comprising over 6 million children were included.
- Random effects models were used to pool hazard ratios (HRs) and 95% confidence intervals (CIs) for ASD and ADHD risks.
Main Results:
- Gestational valproate exposure was linked to a significant increase in ASD risk (aHR, 3.10) and a modest increase in ADHD risk (aHR, 1.62).
- High-dose valproate (> 1.0 g/day) exposure substantially elevated ASD risk (aHR, 6.32).
- Increased ASD risk was also observed in monotherapy and discordant sibling pair analyses.
Conclusions:
- Gestational valproate exposure is associated with increased risks of ASD and ADHD.
- The risk of ASD is dose-dependent, with higher risks observed at doses ≥ 1000 mg/day.
- Findings support strong recommendations against valproate use in women of childbearing potential, particularly during pregnancy.
Introduction:
Gestational exposure to valproate has been associated with a wide range of adverse pregnancy outcomes, including major congenital malformations in offspring. However, to date, no meta-analysis has comprehensively examined the risk of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children gestationally exposed to valproate.
Methods:
We searched MEDLINE, Embase, and Scopus from inception until 15 May 2024 for relevant English-language articles. Primary outcomes of interest were the risk of ASD and ADHD, two independent primary outcomes, in children exposed to valproate anytime during pregnancy relative to unexposed children. Secondary outcomes were trimester-wise analyses of risk. We used a random effects model to pool the overall and trimester-wise hazard ratios (HRs) and obtained 95% confidence intervals (CIs), separately for the risks of ASD and ADHD. Study quality was assessed using the Joanna Briggs Institute (JBI) critical appraisal checklist.
Results:
Eight cohort studies (pooled N = 6,033,300) met our search criteria. Anytime gestational exposure to valproate was associated with a large increase in the risk of ASD (adjusted HR [aHR], 3.10; 95% confidence interval [CI], 2.24-4.28; N = 1,841,198) and a modest increase in the risk of ADHD (aHR, 1.62; 95% CI, 1.30-2.01; N = 24,295). The findings in sensitivity analyses for both outcomes were generally consistent with those of the main analyses. Notably, anytime gestational exposure to high-dose valproate (> 1.0 to 1.1 g/day) was associated with a substantially elevated risk of ASD (aHR, 6.32; 95% CI, 3.12-12.80, N = 1,719,825). Likewise, in monotherapy (aHR, 4.21; 95% CI, 2.97-5.95; N = 1,745,253) and discordant sibling pair (aHR, 6.42; 95% CI, 2.02-20.42; N = 1133) analyses, the risk of ASD was substantially elevated.
Conclusion:
Gestational exposure to valproate was associated with an increased risk of ASD and ADHD; the risks for ASD were greater at doses ≥ 1000 mg/day. These findings add to the literature that strongly discourages the use of valproate by women of childbearing age, especially during pregnancy.
More Related Videos
19:57The Use of Trace Eyeblink Classical Conditioning to Assess Hippocampal Dysfunction in a Rat Model of Fetal Alcohol Spectrum Disorders
Published on: August 5, 2017
07:13Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C
Published on: March 25, 2016
Related Concept Videos
01:19Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:07Teratogenicity
01:28Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
01:35Pedigree Analysis